Vanda's Hetlioz Hits Phase III Goal in Delayed Sleep-Wake Phase Disorder
VNDA sits 30% above its 52-week low of $4.27.
Summary
Vanda announced positive Phase III results for Hetlioz (tasimelteon) in Delayed Sleep-Wake Phase Disorder, meeting the primary endpoint with a 37.1-minute sleep onset shift versus placebo and no new safety signals. This is a meaningful clinical win for a company whose Hetlioz franchise has been under severe pressure—Q2 sales cratered 66% and the company posted a $62.5M loss. The data could support a label expansion and revive a key revenue stream, though regulatory and commercial hurdles remain. The company's cash position of $170M and a looming 100% tariff on drug imports add urgency to this development. Watch for a potential sNDA filing and FDA review timeline.
At the time of this announcement, VNDA was trading at $5.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $304.1M. The 52-week trading range was $4.27 to $9.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.